LAVINIA DRAMBAREAN: Open Payments
NPI 1871849372 · HATTIESBURG, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$180,189 in 427 payments from 27 companies in 2025. Trend: 2023 $52,652 · 2024 $129,066 · 2025 $180,189
Speaker / faculty: $120,719Travel & lodging: $46,555Food & beverage: $7,933Consulting: $4,735Education: $247
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 65 | $84,125 |
| Lilly USA, LLC | 56 | $31,159 |
| ABBVIE INC. | 76 | $21,772 |
| Incyte Corporation | 32 | $12,454 |
| Regeneron Healthcare Solutions, Inc. | 37 | $11,793 |
| GENZYME CORPORATION | 17 | $9,072 |
| Eli Lilly and Company | 3 | $3,695 |
| E.R. Squibb & Sons, L.L.C. | 11 | $3,002 |
| LEO Pharma Inc. | 19 | $1,281 |
| Novartis Pharmaceuticals Corporation | 23 | $311 |
Products named: TREMFYA, DUPIXENT, TALTZ, EBGLYSS, OPZELURA, SKYRIZI, RINVOQ, Sotyktu.
Industry payments across MS — which companies pay providers there.
